Back to Search Start Over

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Authors :
Raimon Sanmartí
Jesús Sanz-Sanz
Rosario García-Vicuña
Benito Dorantes-Calderón
Carmen Martinez-Fernandez
Paloma Vela
Isidoro González-Álvaro
José Andrés Román Ivorra
José Luis Poveda-Andrés
Olatz Ibarra-Barrueta
Santiago Muñoz-Fernández
Emilio Martín-Mola
Blanca Hernández-Cruz
Alberto Morell-Baladrón
Alicia Herrero-Ambrosio
Emilio Monte-Boquet
Francisco Javier de Toro-Santos
[Gonzalez-Alvaro, Isidoro
Garcia-Vicuna, Rosario] Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa, Rheumatol Serv, Madrid 28006, Spain
[Herrero-Ambrosio, Alicia] IdiPaz, Hosp Univ La Paz, Hosp Pharm Serv, Madrid, Spain
[Martin-Mola, Emilio] Univ Autonoma Madrid, IdiPaz, Hosp Univ La Paz, Rheumatol Serv, Madrid, Spain
[Morell-Baladron, Alberto] Hosp Univ La Princesa, Hosp Pharm Serv, Madrid 28006, Spain
[Sanz-Sanz, Jesus] Hosp Puerta de Hierro, Rheumatol Serv, Madrid, Spain
[Munoz-Fernandez, Santiago] Univ Europea Madrid, Hosp Univ Infanta Sofia, Rheumatol Serv, Madrid, Spain
Source :
Rheumatology (Oxford, England), ABACUS. Repositorio de Producción Científica, Universidad Europea (UEM), RUC. Repositorio da Universidade da Coruña, instname, Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid
Publication Year :
2014

Abstract

The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases Sociedad Española de Reumatología 4.524 JCR (2015) Q1, 6/32 Rheumatology UEM

Details

ISSN :
14620332
Volume :
54
Issue :
7
Database :
OpenAIRE
Journal :
Rheumatology (Oxford, England)
Accession number :
edsair.doi.dedup.....1921c7ea66bc4d43aa73edcdb91f2465